SEATTLE--ZymoGenetics Inc. has begun construction of a new 46,000-square-foot, $12 million R&D facility located adjacent to the company's headquarters. The new building will later be expanded to 78,500 square feet.
ZymoGenetics is the North American Health Care Drug Discovery unit of the Danish pharmaceutical company Novo Nordisk A/S. It employs over 250 staff in the pursuit of bioinformatics-driven discovery of therapeutic proteins.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
